Bone Marrow Mononuclear Cells (BMMCs)
Bone marrow mononuclear cells (BMMC), viably frozen in serum free media and DMSO.
Advancing your research into hematological malignancies, immunology, and other related areas requires access to high quality human bone marrow mononuclear cells. Precision for Medicine has an inventory of BMMCs collected from disease-state donors, as well as healthy donors with longitudinal data. Custom collections for BMMCs are also available with matched PBMCs and/or BMA supernatant.
Ethically-sourced BMMCs for your research
As an excellent source of hematopoietic stem cells and biomarkers for a range of hematological and immune system disorders, bone marrow mononuclear cells (BMMCs) are critical for assay development and validation during diagnostic and therapeutic development.
- Isolated from bone marrow aspirate with ≥90% viability
- Available from healthy or disease-state donors
- Consented and IRB approved for research
- Unique donor lots and demographic profiles available from inventory
Precision can provide the following characterization with your BMMC samples
- High-resolution, Class I and II HLA typing
- Donor demographics and medical history
- Matched PBMCs and/or BMA supernatant
- ELISpot for CEF and CMV response
- Viability and purity data
BMMCs to acclerate your diagnostic and therapeutic development
Discover Precision’s viable cell products
Alongside our BMMCs, Precision offers various cellular products from leukopaks to purified cell subsets – collected at our in-house apheresis center.
Precision’s global network of specialty labs bring you customized processing services for your BMMCs
-
Explore
ELISpot and Fluorospot
ELISpot and FluoroSpot - including custom assays in support of gene therapy immunogenicity - from preclinical through clinical development
-
Explore
Flow Cytometry
Standard and spectral flow cytometry, on both research-grade and CLIA-validated instruments -
Explore
ELISA
Services using the gold standard for quantitative antibody-based bioanalysis, with specialization in immunogenicity assay development